Antares Pharma Announces the Issuance of a New Patent on VIBEX Device Platform
Antares Pharma (NASDAQ: ATRS) today announced the issuance of U.S. Patent number 8,419,686 which relates to the device-injection site contacting interface. The interface design is applicable to the entire Antares VIBEX™ injector device platform.
Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, “This is another example of the importance of our intellectual property strategy as we continue to actively protect the enhanced device technologies being applied to both established and new drugs. Over the past fifteen months, Antares has filed 30 patent applications and has received 8 new patents including this most recent issuance.” Dr. Wotton continued, “This patent focuses on the interface between injection devices and the patient. It demonstrates that Antares understands that self-injection requires unique device features for the home setting where a growing number of injectables are being used.”
U.S. Patent 8,419,686 describes a unique device collar design which comes in contact with the skin surrounding the injection site when the injector is used. This interface design can be applied to all Antares' VIBEX™ devices, especially the VIBEX™ Quick Shot (QS) which offers a dose capacity up to 1 mL or larger volumes.
About Antares Pharma
Antares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company is developing OTREXUP™, a combination product for the delivery of methotrexate using Medi-Jet™ technology for the treatment of rheumatoid arthritis, poly-articular-course juvenile rheumatoid arthritis and psoriasis, as well as VIBEX™ QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX™ disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet® and Zomajet® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin® human growth hormone (hGH), VIBEX™ epinephrine and several other products. Antares Pharma's partnership with Ferring includes Zomacton® hGH. In the U.S. Antares has received FDA approval for Gelnique 3%™, a treatment for overactive bladder that is marketed by Actavis. Elestrin® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company's reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company's corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are indicated by the words “may,” “will,” “plans,” “intends,” “believes,” “expects,” “anticipates,” “potential,” “could,” “would,” “should,” and similar expressions. Such forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties include, among others, changes in revenue growth and difficulties or delays in the initiation, progress, or completion of product development. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.
© 2014 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.